Basic Information Experimental Physicochemical Property Pharmacokinetic/Toxicokinetic Property Maximum Dosage Drug Property Radar Chart

Basic Information

Drug ID DDPD00860 ...
Drug Name Prednisolone
Molecular Weight 360.444
Molecular Formula C21H28O5
CAS Number 50-24-8
SMILES [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
External Links
DRUGBANK DB00860
PubChem Compound 5755
Drugs.com Drugs.com Drug Page

Experimental Physicochemical Property

Property Name Property Value Unit Raw Value Raw Unit Reference
Log P 1.62 - 1.62 - HANSCH,C ET AL. (1995)
Melting Point 235.0 ℃ 235 ℃ PhysProp
Water Solubility 223.0 mg/L 223 mg/L YALKOWSKY,SH & DANNENFELSER,RM 1992)
Log S -3.21 - -3.21 - ADME Research, USCD

Pharmacokinetic/ Toxicokinetic Property

Property Name Property Value Unit Raw Value Raw Unit Annotation Factor Reference
Bioavailability 70.0 % 70 % PO, oral; DRUGBANK
Bioavailability 82.0 % 82±13 % PO, oral; The Pharmacological Basis of Therapeutics
C Max 728.0 ng/ml 113-1343 ng/ml PO, oral; DRUGBANK
C Max 458.0 ng/ml 458±150 ng/ml PO, oral; Male, men; adults; normal,healthy; The Pharmacological Basis of Therapeutics
T Max 1.8 h 1-2.6 h PO, oral; DRUGBANK
T Max 1.5 h 1.5±0.5 h PO, oral; Male, men; adults; normal,healthy; The Pharmacological Basis of Therapeutics
Clearance 0.0900 L/h/kg 0.09 L/h/kg DRUGBANK
Clearance 0.12 L/h/kg 0.12 L/h/kg DRUGBANK
Clearance 0.0600 L/h/kg 1.0±0.16 ml/min/kg Elderly ↓ ;Hepatitis, Hep → ;Hepatic cirrhosis, cirr ↓ ;hyperthyroid, HTh → ;nephritic syndrome → ;chronic respiratory insufficiency → ;Cushing's Disease → ;Somking → ; The Pharmacological Basis of Therapeutics
Clearance 0.17 L/h/kg 2.9 ml/min/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Volume of Distribution 29.3 L 29.3 L DRUGBANK
Volume of Distribution 44.2 L 44.2 L DRUGBANK
Volume of Distribution 0.42 L/kg 0.42±0.11 L/kg Elderly ↓ ;Obesity ↓ ;hyperthyroid, HTh ↓ ;Hepatitis, Hep → ;Cushing's Disease → ;RD, renal impairment, Renal disease，including uremia → ;chronic respiratory insufficiency → ;nephritic syndrome → ;increasing doses ↑ ; The Pharmacological Basis of Therapeutics
Volume of Distribution 0.86 L/kg 0.86 L/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Half-life 2.8 h 2.1-3.5 h elimination half-life; Children ↓ ;hepatopathy，LD ↑ ; DRUGBANK
Half-life 2.2 h 2.2±0.5 h Hepatitis, Hep → ;Cushing's Disease → ;RD, renal impairment, Renal disease，including uremia → ;chronic respiratory insufficiency → ;nephritic syndrome → ;hyperthyroid, HTh ↓ ;Somking → ;Age ↑ ; The Pharmacological Basis of Therapeutics
Half-life 3.4 h 3.4 h intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Toxicity LD50 2000.0 mg/kg 2.0 g/kg Intraperitoneal, IP; Rattus, Rat; DRUGBANK
Toxicity LD50 65.0 mg/kg 65.0 mg/kg Intraperitoneal, IP; mouse; DRUGBANK
Toxicity LD50 147.0 mg/kg 147.0 mg/kg subcutaneous injection, SC; Rattus, Rat; DRUGBANK
Toxicity LD50 3500.0 mg/kg >3500 mg/kg subcutaneous injection, SC; mouse; DRUGBANK
Toxicity LD50 1680.0 mg/kg 1680.0 mg/kg PO, oral; mouse; DRUGBANK
Toxicity TDLo 0.64 mg/kg/day 9.0 mg/kg/2W PO, oral; Male, men; human, homo sapiens; DRUGBANK
Toxicity TDLo 1.1 mg/kg/day 14.0 mg/kg/13D PO, oral;  Female, women; human, homo sapiens; DRUGBANK
Eliminate Route 98.0 % >98 % Urinary excretion; DRUGBANK
Eliminate Route 26.0 % 26±9 % Urinary excretion; Unchanged drug; Elderly ↓ ;hyperthyroid, HTh ↓ ; The Pharmacological Basis of Therapeutics
Protein Binding 78.0 % 65-91 % normal,healthy; patients; DRUGBANK
Protein Binding 92.5 % 90-95 % Elderly ↓ ;hypoalbuminemia Alb ↓ ;nephritic syndrome ↓ ;hyperthyroid, HTh ↓ ;Hepatic cirrhosis, cirr ↓ ;Hepatitis, Hep → ; The Pharmacological Basis of Therapeutics
Protein Binding 70.0 % ~70 % The Pharmacological Basis of Therapeutics

Maximum Dosage

Not Available

Drug Property Radar Chart

...

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1